All Stories

  1. Sex-stratified mortality estimates in people with schizophrenia: A systematic review and meta-analysis of cohort studies of 2,700,825 people with schizophrenia
  2. The challenges of antipsychotic polypharmacy
  3. Antipsychotic Monotherapy vs Polytherapy for Pneumonia Risk—Reply
  4. Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder
  5. Effects of antipsychotic treatment on cardio-cerebrovascular related mortality in schizophrenia: A subanalysis of a systematic review and meta-analysis with meta-regression of moderators
  6. Dosing levels of antipsychotics and mood stabilizers in bipolar disorder: A Nationwide cohort study on relapse risk and treatment safety
  7. Severe side effects of the most effective schizophrenia medication
  8. Pneumonia Risk, Antipsychotic Dosing, and Anticholinergic Burden in Schizophrenia
  9. Association of obesity to reaction time and visual memory in schizophrenia
  10. Characteristics of high-dose benzodiazepine use: nationwide cohort study on new benzodiazepine users with 5-year follow-up
  11. Aberrant type 2 dopamine receptor availability in violent offenders with psychopathy
  12. Astrocytes Regulate Neuronal Network Burst Frequency Through NMDA Receptors in a Species- and Donor-Specific Manner
  13. Cardiovascular mortality in bipolar disorder: Population‐based cohort study
  14. Long-term persistence of the risk of agranulocytosis with clozapine compared with other antipsychotics: a nationwide cohort and case–control study in Finland
  15. Real‐world effectiveness of antidepressants, antipsychotics and their combinations in the maintenance treatment of psychotic depression. Evidence from within‐subject analyses of two nationwide cohorts
  16. Medication use and sickness absence from work in bipolar disorder: a nationwide register‐based study
  17. Antipsychotic Use and Risk of Breast Cancer in Women With Severe Mental Illness: Replication of a Nationwide Nested Case–Control Database Study
  18. Integrative metabolomics-genomics analysis identifies key networks in a stem cell-based model of schizophrenia
  19. Antipsychotic Use and Psychiatric Hospitalization in First-Episode Non-affective Psychosis and Cannabis Use Disorder: A Swedish Nationwide Cohort Study
  20. Development and Validation of a Machine Learning–Based Model of Mortality Risk in First-Episode Psychosis
  21. Navigated and individual α-peak-frequency–guided transcranial magnetic stimulation in male patients with treatment-refractory schizophrenia
  22. Regional differences in mortality risk and in attenuating or aggravating factors in schizophrenia: A systematic review and meta-analysis
  23. Efficacy and effectiveness of antipsychotics in schizophrenia: network meta-analyses combining evidence from randomised controlled trials and real-world data
  24. Relative Risk of Breast Cancer Associated With Prolactin-Increasing Antipsychotic Use
  25. Long-term benzodiazepine use and risk of labor market marginalization in Finland: A cohort study with 5-year follow-up
  26. Effect of severity of depression on augmentation of antidepressant medication in young adults with depression
  27. Non-adherence to mood stabilizers and antipsychotics among persons with bipolar disorder – A nationwide cohort study
  28. β2-Adrenoceptor Agonists in Asthma or Chronic Obstructive Pulmonary Disease and Risk of Parkinson’s Disease: Nested Case-Control Study
  29. Real-world effectiveness of antidepressant use in persons with schizophrenia: within-individual study of 61,889 subjects
  30. Safety of Antipsychotic Polypharmacy Versus Monotherapy in a Nationwide Cohort of 61,889 Patients With Schizophrenia
  31. Association of pharmacological treatments and real‐world outcomes in borderline personality disorder
  32. Cohort profile: SUPER-Finland – the Finnish study for hereditary mechanisms of psychotic disorders
  33. Functional Characterization of Six SLCO1B1 (OATP1B1) Variants Observed in Finnish Individuals with a Psychotic Disorder
  34. Association of Treatment-Resistant Depression With Patient Outcomes and Health Care Resource Utilization in a Population-Wide Study
  35. Associations Between Polygenic Risk Score Loading, Psychosis Liability, and Clozapine Use Among Individuals With Schizophrenia
  36. Association of Pharmacological Treatments and Hospitalization and Death in Individuals With Amphetamine Use Disorders in a Swedish Nationwide Cohort of 13 965 Patients
  37. Psychotic depression and deaths due to suicide
  38. Effectiveness of Antipsychotic Use for Reducing Risk of Work Disability: Results From a Within-Subject Analysis of a Swedish National Cohort of 21,551 Patients With First-Episode Nonaffective Psychosis
  39. Validation of the collaborative outcomes study on health and functioning during infection times (COH-FIT) questionnaire for adults
  40. Factors and their weight in reducing life expectancy in schizophrenia
  41. Antipsychotic Use and Risk of Low-Energy Fractures in People With Schizophrenia: A Nationwide Nested Case-Control Study in Finland
  42. Mortality in psychotic depression: 18-year follow-up study
  43. Twenty‐year medication use trends in first‐episode bipolar disorder
  44. Women with Schizophrenia-Spectrum Disorders After Menopause: A Vulnerable Group for Relapse
  45. Mu-opioid receptor system modulates responses to vocal bonding and distress signals in humans
  46. Real‐world effectiveness of mood stabilizer use in schizophrenia
  47. Allopurinol, dipyridamole and calcium channel blockers in the treatment of bipolar disorder – A nationwide cohort study
  48. Associations between antipsychotic use, substance use and relapse risk in patients with schizophrenia: real-world evidence from two national cohorts
  49. Comparative effectiveness of mood stabilizers and antipsychotics in the prevention of hospitalization after lithium discontinuation in bipolar disorder
  50. Healthcare utilization, costs, and productivity losses in treatment-resistant depression in Finland – a matched cohort study
  51. Clozapine and the risk of haematological malignancies – Authors' reply
  52. Courses of treatment and risk factors for treatment-resistant depression in Finnish primary and special healthcare: A nationwide cohort study
  53. Real-world effectiveness studies of low doses of antipsychotics – Authors' reply
  54. Differences in psychosocial functioning between psychotic disorders in the Finnish SUPER study
  55. Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia
  56. Mortality in people with schizophrenia: a systematic review and meta‐analysis of relative risk and aggravating or attenuating factors
  57. Long-term treatment with clozapine and other antipsychotic drugs and the risk of haematological malignancies in people with schizophrenia: a nationwide case-control and cohort study in Finland
  58. Half a century of research on antipsychotics and schizophrenia: A scientometric study of hotspots, nodes, bursts, and trends
  59. Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorders
  60. Real-world effectiveness of antipsychotic doses for relapse prevention in patients with first-episode schizophrenia in Finland: a nationwide, register-based cohort study
  61. Aberrant motor contagion of emotions in psychopathy and high-functioning autism
  62. Female Psychopathy and Mortality
  63. Primary Nonadherence to Antipsychotic Treatment Among Persons with Schizophrenia
  64. Clinical and societal burden of incident major depressive disorder: A population‐wide cohort study in Stockholm
  65. Representation and Outcomes of Individuals With Schizophrenia Seen in Everyday Practice Who Are Ineligible for Randomized Clinical Trials
  66. Implementation of CYP2D6 copy-number imputation panel and frequency of key pharmacogenetic variants in Finnish individuals with a psychotic disorder
  67. Real‐world effectiveness of pharmacological treatments of opioid use disorder in a national cohort
  68. The collaborative outcomes study on health and functioning during infection times in adults (COH-FIT-Adults): Design and methods of an international online survey targeting physical and mental health effects of the COVID-19 pandemic
  69. Brain structural alterations in autism and criminal psychopathy
  70. The iPSC perspective on schizophrenia
  71. Contribution of astrocytes to familial risk and clinical manifestation of schizophrenia
  72. Switches and early discontinuations of antidepressant medication in young adults with depression
  73. Exploring the relation between high-activity COMT Val158Met genotype and psychopathy in male offenders
  74. Correspondence regarding De Girolamo et al., 2021 ‘A multinational case–control study comparing forensic and non-forensic patients with schizophrenia spectrum disorders: the EU-VIORMED project’
  75. Reaction Time and Visual Memory in Connection to Hazardous Drinking Polygenic Scores in Schizophrenia, Schizoaffective Disorder and Bipolar Disorder
  76. Clozapine, Long-Acting Injectables (and Polypharmacy?) Superior in U.S. and International Registries
  77. Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland
  78. Reaction Time and Visual Memory in Connection to Alcohol Use in Persons with Bipolar Disorder
  79. Associations of age, sex, sexual abuse, and genotype with monoamine oxidase a gene methylation
  80. Antipsychotics Use Is Associated With Greater Adherence to Cardiometabolic Medications in Patients With Schizophrenia: Results From a Nationwide, Within-subject Design Study
  81. Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations
  82. Antipsychotic discontinuation: mind the patient and the real-world evidence
  83. Long-term Continuity of Antipsychotic Treatment for Schizophrenia: A Nationwide Study
  84. Continuity of antipsychotic medication use among migrant and Finnish-born populations with a psychotic disorder: a register-based study
  85. Molecular signaling pathways underlying schizophrenia
  86. Reaction Time and Visual Memory in Connection with Alcohol Use in Schizophrenia and Schizoaffective Disorder
  87. Risk Factors, Incidence, and Outcomes of Neuroleptic Malignant Syndrome on Long-Acting Injectable vs Oral Antipsychotics in a Nationwide Schizophrenia Cohort
  88. HLA-DQB1 6672G>C (rs113332494) is associated with clozapine-induced neutropenia and agranulocytosis in individuals of European ancestry
  89. Brain Basis of Psychopathy in Criminal Offenders and General Population
  90. Hip Fracture Risk in Antiepileptic Drug Initiators and Non-Initiators with Alzheimer’s Disease
  91. Registry-based studies: What they can tell us, and what they cannot
  92. Incidence of schizophrenia and influence of prenatal and infant exposure to viral infectious diseases
  93. Changes in the metabolic profile of human male postmortem frontal cortex and cerebrospinal fluid samples associated with heavy alcohol use
  94. Morbidity and mortality in schizophrenia with comorbid substance use disorders
  95. Voluntary patient safety incidents reporting in forensic psychiatry—What do the reports tell us?
  96. Long-Term Real-World Effectiveness of Pharmacotherapies for Schizoaffective Disorder
  97. Effectiveness of pharmacotherapies for delusional disorder in a Swedish national cohort of 9076 patients
  98. Adenosine modulators and calcium channel blockers as add-on treatment for schizophrenia
  99. Risk of labour market marginalisation among young refugees and non-refugee migrants with common mental disorders
  100. Real‐world effectiveness of pharmacological treatments of alcohol use disorders in a Swedish nation‐wide cohort of 125 556 patients
  101. Long-Term Continuity of Antipsychotic Treatment for Schizophrenia: A Nationwide Study
  102. Antipsychotic use among persons with schizophrenia in Sweden and Finland, trends and differences
  103. Rejoinder to rejoinder to commentary
  104. Suicide mortality and use of psychotropic drugs in patients hospitalized due to bipolar disorder: A Finnish nationwide cohort study
  105. Employment among people with schizophrenia or bipolar disorder: A population‐based study using nationwide registers
  106. Medication management of antipsychotic treatment in schizophrenia—A narrative review
  107. Causes of death in a nationwide cohort of community-dwellers with Alzheimer’s disease
  108. P.810Real-world effectiveness of mood stabilizer use in persons with schizophrenia
  109. Incidence of and Characteristics Associated With Long-term Benzodiazepine Use in Finland
  110. Commentary on Robert Whitaker's viewpoint
  111. Detection of medications associated with Alzheimer's disease using ensemble methods and cooperative game theory
  112. Corrigendum to “Monoamine oxidase A genotype and methylation moderate the association of maltreatment and aggressive behaviour” [Behav. Brain Res. 382 (2020) 112476]
  113. Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis
  114. Comparative Effectiveness of Antipsychotics for Risk of Attempted or Completed Suicide Among Persons With Schizophrenia
  115. Length of Hospital Stay for Hip Fracture and 30-Day Mortality in People With Alzheimer’s Disease: A Cohort Study in Finland
  116. Medication Use and Health Care Utilization After a Cost-sharing Increase in Schizophrenia
  117. Persistence of Antipsychotic Use After Clozapine Discontinuation: A Real‐World Study Across Antipsychotics
  118. Antiepileptic drug use and mortality among community-dwelling persons with Alzheimer disease
  119. Risk and risk factors for disability pension among patients with treatment resistant depression– a matched cohort study
  120. The clinical course of schizophrenia in women and men—a nation-wide cohort study
  121. T208. EFFECTIVENESS OF PHARMACOLOGICAL THERAPIES FOR DELUSIONAL DISORDER
  122. Monoamine oxidase A genotype and methylation moderate the association of maltreatment and aggressive behaviour
  123. A Systematic Literature Review of Neuroimaging of Psychopathic Traits
  124. Asthma and Chronic Obstructive Pulmonary Disease as a Comorbidity and Association with the Choice of Antidementia Medication Among Persons with Alzheimer’s Disease
  125. Prevalence of cardiovascular drug use before and after diagnosis of Alzheimer's disease
  126. Health and work disability outcomes in parents of patients with schizophrenia associated with antipsychotic exposure by the offspring
  127. Use of antidepressants and mood stabilizers in persons with first-episode schizophrenia
  128. 20‐year follow‐up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20)
  129. In the aftermath of clozapine discontinuation: comparative effectiveness and safety of antipsychotics in patients with schizophrenia who discontinue clozapine
  130. The Risk of Head Injuries Associated With Antipsychotic Use Among Persons With Alzheimer's disease
  131. Opioid Use After Hospital Care due to Hip Fracture Among Community-Dwelling Persons With and Without Alzheimer’s Disease
  132. Accumulation of Hospital Days Among Antipsychotic Initiators With Alzheimer's Disease
  133. Metformin and Risk of Alzheimer’s Disease Among Community-Dwelling People With Diabetes: A National Case-Control Study
  134. Correction: Neurobiological roots of psychopathy
  135. Substance Abuse and Excessive Mortality Among Forensic Psychiatric Patients: A Finnish Nationwide Cohort Study
  136. Sex-specific transcriptional and proteomic signatures in schizophrenia
  137. Neurobiological roots of psychopathy
  138. Predictors of high hospital care and medication costs and cost trajectories in community-dwellers with Alzheimer’s disease
  139. Cortical structure abnormalities in females with conduct disorder prior to age 15
  140. Adherence to psychotropic medication in completed suicide in Sweden 2006–2013: a forensic-toxicological matched case-control study
  141. Psychosis breakthrough on antipsychotic maintenance: results from a nationwide study
  142. Hospital-Treated Pneumonia Associated with Opioid Use Among Community Dwellers with Alzheimer’s Disease
  143. Antiepileptic Drugs and Accumulation of Hospital Days Among Persons With Alzheimer's Disease
  144. Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia
  145. Increased [³H]quisqualic acid binding density in the dorsal striatum and anterior insula of alcoholics: A post-mortem whole-hemisphere autoradiography study
  146. Long-term thiazide use and risk of low-energy fractures among persons with Alzheimer’s disease—nested case-control study
  147. Changes in patient safety culture: A patient safety intervention for Finnish forensic psychiatric hospital staff
  148. Long-acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: A systematic review
  149. Trajectories of sickness absence, disability pension and unemployment in young immigrants with common mental disorders
  150. Antiepileptic Drug Use Is Associated with an Increased Risk of Pneumonia Among Community-Dwelling Persons with Alzheimer’s Disease-Matched Cohort Study
  151. Incidence of head injury and traumatic brain injury among people with Alzheimer’s disease
  152. Manifesto for an international digital mental health network
  153. Risk of Treatment Failure: Response to Ghosh and Noble
  154. Associations of Psychopathic Traits With Local and Global Brain Network Topology in Young Adult Women
  155. Response to the editorial on antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia
  156. Concomitant use of benzodiazepines and opioids in community‐dwelling older people with or without Alzheimer's disease—A nationwide register‐based study in Finland
  157. Duration of new antidepressant use and factors associated with discontinuation among community-dwelling persons with Alzheimer’s disease
  158. Comorbid opioid use is undertreated among forensic patients with schizophrenia
  159. Psychotropic drugs use and psychotropic polypharmacy among persons with Alzheimer's disease
  160. Incidence and prevalence of antiepileptic drugs use in persons with Alzheimer's disease.
  161. Systemic Estrogen Use and Discontinuation After Alzheimer’s Disease Diagnosis in Finland 2005–2012: A Nationwide Exposure-Matched Cohort Study
  162. Incident opioid use and risk of hip fracture among persons with Alzheimer disease: a nationwide matched cohort study
  163. Antipsychotic Use and the Risk of Initiating Medication for Benign Prostate Hyperplasia in Persons With Alzheimer Disease
  164. Antiepileptic Drug Use and the Risk of Stroke Among Community‐Dwelling People With Alzheimer Disease: A Matched Cohort Study
  165. Burden for Parents of Patients With Schizophrenia—A Nationwide Comparative Study of Parents of Offspring With Rheumatoid Arthritis, Multiple Sclerosis, Epilepsy, and Healthy Controls
  166. Risk of Treatment Failure: Response to Czobor and Volavka
  167. 20-Year Nationwide Follow-Up Study on Discontinuation of Antipsychotic Treatment in First-Episode Schizophrenia
  168. Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia
  169. Hospitalization after Oral Antibiotic Initiation in Finnish Community Dwellers with and without Alzheimer’s Disease: Retrospective Register-Based Cohort Study
  170. Mortality in schizophrenia: 30‐year nationwide follow‐up study
  171. The risk of Alzheimer's disease associated with benzodiazepines and related drugs: a nested case–control study
  172. Editorial: let's take a break from studying the PPI‐fracture association—Authors’ reply
  173. Trends in the long‐term use of benzodiazepine anxiolytics and hypnotics: A national register study for 2006 to 2014
  174. Cause-specific mortality in Finnish forensic psychiatric patients
  175. Real-world Effectiveness of Pharmacologic Treatments for the Prevention of Rehospitalization in a Finnish Nationwide Cohort of Patients With Bipolar Disorder
  176. Associations of monoamine oxidase A gene first exon methylation with sexual abuse and current depression in women
  177. Comparison of dispensed medications and forensic‐toxicological findings to assess pharmacotherapy in the Swedish population 2006 to 2013
  178. Use of Antiepileptic Drugs and Dementia Risk—an Analysis of Finnish Health Register and German Health Insurance Data
  179. Impact of opioid initiation on antipsychotic and benzodiazepine and related drug use among persons with Alzheimer's disease
  180. Proton pump inhibitor use and risk of hip fractures among community‐dwelling persons with Alzheimer's disease—a nested case‐control study
  181. Initiation and long‐term use of benzodiazepines and Z‐drugs in bipolar disorder
  182. Platelet monoamine oxidase activity and interpersonal violence in male suicide attempters
  183. Associations Between MAOA‐uVNTR Genotype, Maltreatment, MAOA Methylation, and Alcohol Consumption in Young Adult Males
  184. Amygdala-orbitofrontal structural and functional connectivity in females with anxiety disorders, with and without a history of conduct disorder
  185. Firesetting and general criminal recidivism among a consecutive sample of Finnish pretrial male firesetters: A register-based follow-up study
  186. Comparative Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia—A Nationwide Study With 20-Year Follow-up
  187. Genome-Wide Association Studies of a Broad Spectrum of Antisocial Behavior
  188. No Association Between Proton Pump Inhibitor Use and Risk of Alzheimer’s Disease
  189. Risk of disability pension in first and second generation immigrants: the role of age and region of birth in a prospective population-based study from Sweden
  190. Healthcare use among immigrants and natives in Sweden on disability pension, before and after changes of regulations
  191. Risk of death associated with new benzodiazepine use among persons with Alzheimer disease: A matched cohort study
  192. Nurses’ Views Highlight a Need for the Systematic Development of Patient Safety Culture in Forensic Psychiatry Nursing
  193. De‐escalation techniques used, and reasons for seclusion and restraint, in a forensic psychiatric hospital
  194. Drug exposure in register-based research—An expert-opinion based evaluation of methods
  195. Trajectories and characteristics of work disability before and after acute myocardial infarction
  196. Use of lithium in patients with unipolar depression – Author's reply
  197. Is Alzheimer’s Disease Associated with Previous Opioid Use?
  198. Effects of Scheduled Waiting for Psychotherapy in Patients With Major Depression
  199. Reducing the rehospitalization risk after a manic episode: A population based cohort study of lithium, valproate, olanzapine, quetiapine and aripiprazole in monotherapy and combinations
  200. Risk of head and traumatic brain injuries associated with antidepressant use among community-dwelling persons with Alzheimer’s disease: a nationwide matched cohort study
  201. The Association of Ambient Temperature and Violent Crime
  202. White matter correlates of psychopathic traits in a female community sample
  203. Brain structure abnormalities in young women who presented conduct disorder in childhood/adolescence
  204. Pharmacological treatments and risk of readmission to hospital for unipolar depression in Finland: a nationwide cohort study
  205. Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia
  206. Long-term use of proton pump inhibitors among community-dwelling persons with and without Alzheimer’s disease
  207. Hospital-treated mental and behavioral disorders and risk of Alzheimer's disease: A nationwide nested case-control study
  208. Psychopathy and Mortality
  209. Screening approach for identifying candidate drugs and drug‐drug interactions related to hip fracture risk in persons with Alzheimer disease
  210. Incident Use of a Potentially Inappropriate Medication and Hip Fracture in Community-Dwelling Older Persons With Alzheimer’s Disease
  211. Seasonal variation of hospital violence, seclusion and restraint in a forensic psychiatric hospital
  212. Use of benzodiazepines and related drugs is associated with a risk of stroke among persons with Alzheimer’s disease
  213. Risk of pneumonia associated with incident benzodiazepine use among community-dwelling adults with Alzheimer disease
  214. Risk of Alzheimer’s disease among users of postmenopausal hormone therapy: A nationwide case-control study
  215. Antipsychotic Use and the Risk of Hip Fracture Among Community-Dwelling Persons With Alzheimer’s Disease
  216. Regional changes in psychotropic use among Finnish persons with newly diagnosed Alzheimer’s disease in 2005-2011
  217. Risk of Mortality Associated with Antipsychotic Monotherapy and Polypharmacy Among Community-Dwelling Persons with Alzheimer’s Disease
  218. Anticholinergic Exposure and Risk of Pneumonia in Persons with Alzheimer’s Disease: A Nested Case-Control Study
  219. Antidepressant use and risk of hip fractures among community‐dwelling persons with and without Alzheimer's disease
  220. Risk of Hip Fracture in Benzodiazepine Users With and Without Alzheimer Disease
  221. Antipsychotic Use and Risk of Hospitalization or Death Due to Pneumonia in Persons With and Those Without Alzheimer Disease
  222. Comparison of predictors of hip fracture and mortality after hip fracture in community-dwellers with and without Alzheimer’s disease – exposure-matched cohort study
  223. Use of antidementia drugs and risk of pneumonia in older persons with Alzheimer’s disease
  224. A Comparison of Sex Differences in Psychotropic Medication Use in Older People with Alzheimer’s Disease in the US and Finland
  225. Differences in analgesic use in community‐dwelling persons with and without Alzheimer's disease
  226. Risk Factors for Initiation of Potentially Inappropriate Medications in Community-Dwelling Older Adults with and without Alzheimer’s Disease
  227. Long-term use of opioids for nonmalignant pain among community-dwelling persons with and without Alzheimer disease in Finland: a nationwide register-based study
  228. Real‐world effectiveness of antipsychotics
  229. Add-on mirtazapine improves orgasmic functioning in patients with schizophrenia treated with first-generation antipsychotics
  230. Agreement between PRE2DUP register data modeling method and comprehensive drug use interview among older persons
  231. The effects of a HTR2B stop codon and testosterone on energy metabolism and beta cell function among antisocial Finnish males
  232. Fire-setting performed in adolescence or early adulthood predicts schizophrenia: a register-based follow-up study of pre-trial offenders
  233. Drug use in persons with and without Alzheimer's disease aged 90 years or more
  234. Genome-wide association study of antisocial personality disorder
  235. Influence of a HTR2B Stop Codon on Glucagon Homeostasis and Glucose Excursion in Non-Diabetic Men
  236. Cohort profile: the Finnish Medication and Alzheimer's disease (MEDALZ) study
  237. Mortality and Cumulative Exposure to Antipsychotics, Antidepressants, and Benzodiazepines in Patients With Schizophrenia: An Observational Follow-Up Study
  238. Increased steroid hormone dehydroepiandrosterone and pregnenolone levels in post-mortem brain samples of alcoholics
  239. Incidence and Duration of Cumulative Bisphosphonate Use among Community-Dwelling Persons with or without Alzheimer’s Disease
  240. Month and Season of Birth as a Risk Factor for Alzheimer’s Disease: A Nationwide Nested Case-control Study
  241. Incidence of antidepressant use in community‐dwelling persons with and without Alzheimer's disease: 13‐year follow‐up
  242. Conduct disorder in females is associated with reduced corpus callosum structural integrity independent of comorbid disorders and exposure to maltreatment
  243. Impulsive alcohol-related risk-behavior and emotional dysregulation among individuals with a serotonin 2B receptor stop codon
  244. Hospital care and drug costs from five years before until two years after the diagnosis of Alzheimer’s disease in a Finnish nationwide cohort
  245. Incidence of antipsychotic use in relation to diagnosis of Alzheimer's disease among community-dwelling persons
  246. Long-term use of benzodiazepines: Definitions, prevalence and usage patterns – a systematic review of register-based studies
  247. The Incidence of Benzodiazepine and Related Drug Use in Persons with and without Alzheimer’s Disease
  248. Prevalence of Drug Combinations Increasing Bleeding Risk Among Warfarin Users With and Without Alzheimer’s Disease
  249. Long-term use of antipsychotics among community-dwelling persons with Alzheimer׳s disease: A nationwide register-based study
  250. Baseline symptom severity predicts serotonin transporter change during psychotherapy in patients with major depression
  251. Lithium is associated with decrease in all-cause and suicide mortality in high-risk bipolar patients: A nationwide registry-based prospective cohort study
  252. Hospital-treated suicide attempts among Finnish fire setters: a follow-up study
  253. Opioid abuse and hospitalization rates in patients with schizophrenia
  254. A Pilot Study of Group Administered Metacognitive Training (MCT) for Schizophrenia Patients in a High-Security Forensic Setting: Subjective Training Success and Health-Related Quality of Life
  255. Decreased [³H]naloxone Binding in the Dentate Gyrus of Cloninger Type 1 Anxiety-Prone Alcoholics: A Postmortem Whole-Hemisphere Autoradiography Study
  256. Long-term use of benzodiazepines and related drugs among community-dwelling individuals with and without Alzheimer’s disease
  257. Factors Associated with Hospitalization for Blood-Borne Viral Infections Among Treatment-Seeking Illicit Drug Users
  258. Hospitalization in a Cohort Seeking Treatment for Illicit Drug Use in Finland
  259. Psychotropic drugs and homicide: A prospective cohort study from Finland
  260. Potential Years of Life Lost Due to Premature Mortality Among Treatment-Seeking Illicit Drug Users in Finland
  261. From prescription drug purchases to drug use periods – a second generation method (PRE2DUP)
  262. Psychopathic traits among a consecutive sample of Finnish pretrial fire-setting offenders
  263. [3H]Ifenprodil binding in post-mortem brains of Cloninger type 1 and 2 alcoholics: A whole-hemisphere autoradiography study
  264. Characteristics of drug-abusing females with and without children seeking treatment in Helsinki, Finland
  265. Basal insulin secretion, PCL-R and recidivism among impulsive violent alcoholic offenders
  266. Mortality of firesetters: A follow-up study of Finnish male firesetters who underwent a pretrial forensic examination in 1973–1998
  267. Predictors for initiation of pharmacological prophylaxis in patients with newly diagnosed bipolar disorder—A nationwide cohort study
  268. Concomitant Use of Acetylcholine Esterase Inhibitors and Urinary Antispasmodics Among Finnish Community-Dwelling Persons With Alzheimer Disease
  269. Increased Metabotropic Glutamate 2/3 Receptor Binding in the Perigenual Anterior Cingulate Cortex of Cloninger Type 2 Alcoholics: A Whole-Hemisphere Autoradiography Study
  270. Antipsychotic Treatment and Mortality in Schizophrenia
  271. High prevalence of psychotropic drug use among persons with and without Alzheimer׳s disease in Finnish nationwide cohort
  272. Patterns and 14-year trends in mortality among illicit drug users in Finland: The HUUTI study
  273. Genetic background of extreme violent behavior
  274. Lower [3H]Citalopram Binding in Brain Areas Related to Social Cognition in Alcoholics
  275. Corrigendum to “Mortality among clients seeking treatment for buprenorphine abuse in Finland” [Drug Alcohol Depend. 133 (2013) 391–397]
  276. Antipsychotic Doses Among Community-Dwelling Persons With Alzheimer Disease in Finland
  277. Antipsychotic Polypharmacy among a Nationwide Sample of Community-Dwelling Persons with Alzheimer's Disease
  278. The C9ORF72 expansion does not affect the phenotype in Nasu-Hakola disease with the DAP12 mutation
  279. Antidementia drug use among community-dwelling individuals with Alzheimer’s disease in Finland
  280. Association of Socio-Demographic Factors, Sick-Leave and Health Care Patterns with the Risk of Being Granted a Disability Pension among Psychiatric Outpatients with Depression
  281. Mortality among forensic psychiatric patients in Finland
  282. Factors associated with buprenorphine compared to amphetamine abuse among clients seeking treatment in Finland
  283. Metacognitive group training for forensic and dangerous non‐forensic patients with schizophrenia: A randomised controlled feasibility trial
  284. AMPA receptors in post-mortem brains of Cloninger type 1 and 2 alcoholics: A whole-hemisphere autoradiography study
  285. Mortality among clients seeking treatment for buprenorphine abuse in Finland
  286. Patient Safety Culture in Two Finnish State-Run Forensic Psychiatric Hospitals
  287. Previous forensic mental examination is a useful marker indicating effective violence relapse prevention among psychotic patients
  288. Cluster-Randomized Controlled Trial of Reducing Seclusion and Restraint in Secured Care of Men With Schizophrenia
  289. Use of existing data sources in clinical epidemiology: Finnish health care registers in Alzheimer’s disease research – the Medication use among persons with Alzheimer’s disease (MEDALZ-2005) study
  290. Endogenous cannabinoids in amygdala and hippocampus in post-mortem brains of Cloninger type 1 and 2 alcoholics
  291. Cavum septum pellucidum and psychopathy
  292. Exome sequence analysis of Finnish patients with clozapine-induced agranulocytosis
  293. mGluR1/5 receptor densities in the brains of alcoholic subjects: A whole-hemisphere autoradiography study
  294. Violent behaviour in a forensic psychiatric hospital in Finland: an analysis of violence incident reports
  295. Coexisting social conditions and health problems among clients seeking treatment for illicit drug use in Finland: The HUUTI study
  296. Clozapine resistance—Augmentation strategies
  297. Atypical nucleus accumbens morphology in psychopathy: Another limbic piece in the puzzle
  298. Decreased GABAA benzodiazepine binding site densities in postmortem brains of Cloninger type 1 and 2 alcoholics
  299. Extended‐release methylphenidate for treatment of amphetamine/methamphetamine dependence: a randomized, double‐blind, placebo‐controlled trial
  300. Word List Learning in Patients with Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy
  301. Influence of Serotonin Transporter Gene Polymorphism (5-HTTLPR Polymorphism) on the Relation between Brain 5-HT Transporter Binding and Heart Rate Corrected Cardiac Repolarization Interval
  302. Predictors and mediators of add-on mirtazapine-induced cognitive enhancement in schizophrenia – A path model investigation
  303. Using the HCR-20 to Predict Aggressive Behavior among Men with Schizophrenia Living in the Community: Accuracy of Prediction, General and Forensic Settings, and Dynamic Risk Factors
  304. Twelve-year trend in treatment seeking for buprenorphine abuse in Finland
  305. Relationships between pharmacotherapy-induced metabolic changes and improved psychopathology in schizophrenia: data from a mirtazapine and first-generation antipsychotics combination trial
  306. Ketamine in treatment-resistant major depression
  307. Methylphenidate in the treatment of amphetamine dependence: a double-blind randomised, placebo-controlled trial
  308. Naltrexone depot implant in the treatment of co-morbid amphetamine and opioid dependence
  309. Sociodemographic Characteristics and Drug Abuse Patterns of Treatment-Seeking Illicit Drug Abusers in Finland, 1997–2008: The Huuti Study
  310. Description of long-term polypharmacy among schizophrenia outpatients
  311. Outcome of patients after market withdrawal of thioridazine: A retrospective analysis in a nationwide cohort
  312. Rorschach assessment of personality functioning in patients with polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy
  313. Exome Sequencing Followed by Large-Scale Genotyping Suggests a Limited Role for Moderately Rare Risk Factors of Strong Effect in Schizophrenia
  314. Whole-hemisphere autoradiography of 5-HT1B receptor densities in postmortem alcoholic brains
  315. Polypharmacy With Antipsychotics, Antidepressants, or Benzodiazepines and Mortality in Schizophrenia
  316. Naltrexone Implant for the Treatment of Polydrug Dependence: A Randomized Controlled Trial
  317. Cardiovascular morbidity, mortality and pharmacotherapy in patients with schizophrenia
  318. Reply to Drs. Nauta and van Domburg
  319. Examining the effectiveness of antipsychotic medication in first-episode psychosis
  320. Antipsychotic polypharmacy in clozapine resistant schizophrenia: a randomized controlled trial of tapering antipsychotic co-treatment
  321. The Substance Use among Forensic Psychiatric Patients
  322. The net effect of smoking on healthcare and welfare costs. A cohort study
  323. Toward Molecular Psychotherapy of Depression?
  324. The Patient–Therapist Interaction and the Recognition of Affects during the Process of Psychodynamic Psychotherapy for Depression
  325. Statin usage and all‐cause and disease‐specific mortality in a nationwide study
  326. Erratum: Association between medication and risk of suicide, attempted suicide and death in nationwide cohort of suicidal patients with schizophrenia
  327. The place of observational studies in assessing the effectiveness of depot antipsychotics
  328. Cortex and amygdala morphology in psychopathy
  329. A Nationwide Cohort Study of Oral and Depot Antipsychotics After First Hospitalization for Schizophrenia
  330. More evidence on proneurocognitive effects of add-on mirtazapine in schizophrenia
  331. Add‐on mirtazapine improves depressive symptoms in schizophrenia: a double‐blind randomized placebo‐controlled study with an open‐label extension phase
  332. Interrelationship between core interventions and core competencies of forensic psychiatric nursing in Finland
  333. Psychopathy, PCL-R, and MAOA genotype as predictors of violent reconvictions
  334. Psychopathic brain -- an unknown challenge for treatment
  335. Gender differences in brain serotonin transporter availability in panic disorder
  336. Group psychoeducation for long‐term offender patients with schizophrenia: An exploratory randomised controlled trial
  337. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial
  338. Serotonin‐transporter‐linked promoter region polymorphism and serotonin transporter binding in drug‐naïve patients with major depression
  339. Extrapyramidal side-effects and dopamine D2/3receptor binding in substantia nigra
  340. MAOA Alters the Effects of Heavy Drinking and Childhood Physical Abuse on Risk for Severe Impulsive Acts of Violence Among Alcoholic Violent Offenders
  341. Endogenous cannabinoids in post-mortem brains of Cloninger type 1 and 2 alcoholics
  342. EFFECTS OF ADD-ON MIRTAZAPINE ON NEUROCOGNITION IN SCHIZOPHRENIA: AN OPEN LABEL EXTENSION PHASE OF A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY, AND BOTH PHASES
  343. The Intergenerational Cycle of Criminality—Association with Psychopathy*
  344. Seasonal variation of seclusion incidents from violent and suicidal acts in forensic psychiatric patients
  345. Dopamine transporter binding in females with panic disorder may vary with clinical status
  346. Predicting forensic admission among the mentally ill in a multinational setting: A Bayesian modelling approach
  347. Effects of add-on mirtazapine on neurocognition in schizophrenia: a double-blind, randomized, placebo-controlled study
  348. Mortality in patients with schizophrenia – Author's reply
  349. Incidence of cancer and antidepressant medication: Record linkage study
  350. Incidence of cancer and statin usage—Record linkage study
  351. Cardiac repolarization and striatal dopamine transporter function are interrelated
  352. Abnormal hippocampal shape in offenders with psychopathy
  353. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)
  354. Dopamine D2/3 receptor binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and clozapine
  355. Abnormal Cortical Morphology in Offenders with Psychopathy
  356. Low non-oxidative glucose metabolism and violent offending: An 8-year prospective follow-up study
  357. Recidivistic offending and mortality in alcoholic violent offenders: A prospective follow-up study
  358. Altered hemispheric balance of temporal cortex dopamine D2/3 receptor binding in major depressive disorder
  359. Premorbid personality factors in schizophrenia and bipolar disorder: Results from a large cohort study of male conscripts.
  360. The efficacy of lamotrigine in clozapine-resistant schizophrenia: A systematic review and meta-analysis
  361. Antidepressant use and mortality in Finland: a register-linkage study from a nationwide cohort
  362. Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: A double-blind, randomized, placebo-controlled trial
  363. Effects of MAOA‐Genotype, Alcohol Consumption, and Aging on Violent Behavior
  364. 5-HT1A Receptors in the Frontal Cortical Brain Areas in Cloninger Type 1 and 2 Alcoholics Measured by Whole-Hemisphere Autoradiography
  365. Pharmacotherapy of Methamphetamine Addiction: An Update
  366. Brain anatomy of persistent violent offenders: More rather than less
  367. Midbrain serotonin and striatum dopamine transporter binding in double depression: A one-year follow-up study
  368. Association of serotonin transporter promoter regulatory region polymorphism and cerebral activity to visual presentation of food
  369. Predicting Forensic Admission among the Mentally Ill: A Bayesian Approach
  370. Temporal cortex dopamine D2/3 receptor binding in major depression
  371. Striatal dopaminergic terminals in type 1 and type 2 alcoholics measured with [3H]dihydrotetrabenazine and human whole hemisphere autoradiography
  372. Autoradiographic characterization of α2C‐adrenoceptors in the human striatum
  373. Association between medication and risk of suicide, attempted suicide and death in nationwide cohort of suicidal patients with schizophrenia
  374. Characterization of metabolic syndrome among forensic psychiatric inpatients
  375. Antidepressant use and mortality in Finland: A register-linkage study from a nationwide cohort
  376. Cortical dopamine D1 receptors in type 1 and type 2 alcoholics measured with human whole hemisphere autoradiography
  377. Changes in midbrain serotonin transporter availability in atypically depressed subjects after oneyear of psychotherapy
  378. Correlation between the SERT binding densities in hypothalamus and amygdala in cloninger type 1 and 2 alcoholics
  379. Statins are effective in treating dyslipidemia among psychiatric patients using second-generation antipsychotic agents
  380. Body size and violent offending among males in the Northern Finland 1966 birth cohort
  381. Amygdala serotonin transporters in alcoholics measured by whole hemisphere autoradiography
  382. A Comparison of General Adult and Forensic Patients with Schizophrenia Living in the Community
  383. Energy substrate metabolism among habitually violent alcoholic offenders having antisocial personality disorder
  384. Real-world effectiveness of pharmacological treatments in schizophrenia
  385. Violent persons with schizophrenia and comorbid disorders: A functional magnetic resonance imaging study
  386. Reduced midbrain serotonin transporter availability in drug-naïve patients with depression measured by SERT-specific [123I] nor-β-CIT SPECT imaging
  387. A Multisite Study of Community Treatment Programs for Mentally Ill Offenders With Major Mental Disorders
  388. Functional COMT Val158Met Polymorphism, Risk of Acute Coronary Events and Serum Homocysteine: The Kuopio Ischaemic Heart Disease Risk Factor Study
  389. Transmission of violent offending and crime across three generations
  390. A Comparison of Aripiprazole, Methylphenidate, and Placebo for Amphetamine Dependence
  391. A Comparison of Aripiprazole, Methylphenidate, and Placebo for Amphetamine Dependence
  392. Antidepressants and the Risk of Suicide, Attempted Suicide, and Overall Mortality in a Nationwide Cohort
  393. Visualization of the cortical dopamine transporter in type 1 and 2 alcoholics with human whole hemisphere autoradiography
  394. Nucleus accumbens serotonin transporters in alcoholics measured by whole-hemisphere autoradiography
  395. PMH23 PREDICTING VIOLENT OFFENDING AMONG MENTALLY ILL IN A MULTINATIONAL SETTING–NAIVE BAYESIAN FUSION AND MODEL MERGING WITH P-COURSE
  396. Midbrain binding of [123I]nor-β-CIT in atypical depression
  397. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study
  398. Midbrain dopamine D2/3 receptor binding in schizophrenia
  399. Glutamatergic drugs for schizophrenia
  400. Fatal Agranulocytosis 4 Years After Discontinuation of Clozapine
  401. P.2.c.016 Antidepressant use and the risk of suicide, attempted suicide and overall mortality in a nation-wide cohort
  402. Lower serotonin transporter binding in caudate in alcoholics
  403. Seasonal variations in [3H]citalopram platelet binding between healthy controls and violent offenders in Finland
  404. The consequences of Conduct Disorder for males who develop schizophrenia: Associations with criminality, aggressive behavior, substance use, and psychiatric services
  405. Premorbid Intellectual Functioning in Bipolar Disorder and Schizophrenia: Results From a Cohort Study of Male Conscripts
  406. Topiramate Add-On in Treatment-Resistant Schizophrenia
  407. Subcritical water as eluent for chromatographic separation of carbohydrates using cation-exchange resins
  408. Visualisation of the cortical dopamine D3 receptors in alcoholics and controls with human whole-hemisphere autoradiography
  409. Effects of Venlafaxine Treatment on Clozapine Plasma Levels in Schizophrenic Patients
  410. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis
  411. Striatal dopamine D1 receptors in type 1 and 2 alcoholics measured with human whole hemisphere autoradiography
  412. An Outcome of Psychodynamic Psychotherapy: A Case Study of the Change in Serotonin Transporter Binding and the Activation of the Dream Screen
  413. Dopamine and alcoholism: neurobiological basis of ethanol abuse
  414. Reduced brain serotonin transporter binding in patients with panic disorder
  415. A controlled study of tryptophan and cortisol in violent offenders
  416. SPECT imaging of serotonin transporter binding in patients with generalized anxiety disorder
  417. Cortical dopamine D2 receptors in type 1 and 2 alcoholics measured with human whole hemisphere autoradiography
  418. Elevated midbrain serotonin transporter availability in mixed mania: a case report
  419. Distribution of 5-HT7 receptors in the human brain: a preliminary autoradiographic study using []SB-269970
  420. THE MEDIAL TEMPORAL LOBE IN ALCOHOLISM AND PSYCHOPATHOLOGY: EVALUATION BY VOLUMETRIC MRI.
  421. MRI volumetry of the vermis and the cerebellar hemispheres in men with schizophrenia
  422. 123I-?-CIT binding and recovery from depression
  423. Brain serotonin 1A receptor binding in bulimia nervosa
  424. Characteristics and circumstances of homicidal acts committed by offenders with schizophrenia
  425. Comorbid Personality Disorders and Substance Use Disorders of Mentally Ill Homicide Offenders: A Structured Clinical Study on Dual and Triple Diagnoses
  426. Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial
  427. The amygdala and schizophrenia: a volumetric magnetic resonance imaging study in first-episode, neuroleptic-naive patients
  428. Treatment improves serotonin transporter binding and reduces binge eating
  429. P.3.011 Reduced brain serotonin transporter binding in patients with panic disorder
  430. Dopamine D2 receptors and transporters in type 1 and 2 alcoholics measured with human whole hemisphere autoradiography
  431. Total plasma l‐tryptophan, free l‐tryptophan and competing amino acid levels in a homicidal male adolescent with conduct disorder
  432. Dopamine receptors and transporters in the brain reward circuits of type 1 and 2 alcoholics measured with human whole hemisphere autoradiography☆
  433. Ethanol consumption and DRD2 gene TaqI a polymorphism among socially drinking males
  434. Different effect of age on dopamine transporters in the dorsal and ventral striatum of controls and alcoholics
  435. Alcoholics show altered histaminergic neurotransmission in several cortical areas - Preliminary report
  436. Extrastriatal dopamine D2/3 receptor density and distribution in drug-naive schizophrenic patients
  437. Co-eluent effect in partition chromatography. Rhamnose–xylose separation with strong and weak cation-exchangers in aqueous ethanol
  438. Seasonal variation in specific methods of suicide: a national register study of 20 234 Finnish people
  439. Glutamatergic drugs for schizophrenia
  440. Is occupation relevant in suicide?
  441. Prefrontal volumes in habitually violent subjects with antisocial personality disorder and type 2 alcoholism
  442. Use of Statistical Techniques in Studies of Suicide Seasonality, 1970 to 1997
  443. A volumetric MRI study of the entorhinal cortex in first episode neuroleptic-naive schizophrenia
  444. The quantitative risk of violent crime and criminal offending: a case‐control study among the offspring of recidivistic Finnish homicide offenders
  445. Effect of alcohol abuse on human brain histamine and tele-methylhistamine
  446. Serotonin Transporter Distribution and Density in the Cerebral Cortex of Alcoholic and Nonalcoholic Comparison Subjects: A Whole-Hemisphere Autoradiography Study
  447. Analysis of monoamine oxidase A (MAOA) promoter polymorphism in Finnish male alcoholics
  448. Total serum cholesterol level, violent criminal offences, suicidal behavior, mortality and the appearance of conduct disorder in Finnish male criminal offenders with antisocial personality disorder
  449. Seclusion treatment measures and serum cholesterol levels among Finnish male forensic psychiatric patients
  450. Serum lipid levels and violence among Finnish male forensic psychiatric patients
  451. Impaired Temporal Lobe Processing of Preattentive Auditory Discrimination in Schizophrenia
  452. Dopamine Transporter Density and Novelty Seeking Among Alcoholics
  453. Mortality of antisocial male criminals
  454. Free L -tryptophan plasma levels in antisocial violent offenders
  455. Recidivism Among Serious Violent Crime Offenders in Finland
  456. SPECT and neuropsychological performance in severe depression treated with ECT
  457. Measurement of the Striatal Dopamine Transporter Density and Heterogeneity in Type 1 Alcoholics Using Human Whole Hemisphere Autoradiography
  458. Altered frontal lobe function suggested by source analysis of event-related potentials in impulsive violent alcoholics
  459. Dopamine Transporter in vitro Binding and in vivo Imaging in the Brain
  460. Dopamine Transporter in vitro Binding and in vivo Imaging in the Brain
  461. Reduced serotonin transporter binding in binge eating women
  462. Effects of ageing on serotonin transporters in healthy females
  463. A morphometric MRI study of the hippocampus in first-episode, neuroleptic-naı̈ve schizophrenia
  464. The A1 allele of the D2 dopamine receptor gene is associated with high dopamine transporter density in detoxified alcoholics
  465. Dopamine D2/D3-receptor and transporter densities in nucleus accumbens and amygdala of type 1 and 2 alcoholics
  466. Cluster C personality disorder has no independent effect on striatal dopamine transporter densities in major depression
  467. Mortality of antisocial male criminals
  468. Psychopathy and the posterior hippocampus
  469. Characterization of γ-aminobutyrate type A receptors with atypical coupling between agonist and convulsant binding sites in discrete brain regions
  470. In vivo voltammetry with removable carbon fibre electrodes in freely-moving mice: dopamine release during intracranial self-stimulation
  471. Recidivistic Violent Behavior and Axis I and Axis II Disorders
  472. Patterns of dopamine overflow in mouse nucleus accumbens during intracranial self-stimulation
  473. S19.03 Spet studies on outcome of treatment by psychosocial interventions in depression and hysterical paresthesia
  474. Specific binding and laterality of human extrastriatal dopamine D2/D3 receptors in late onset type 1 alcoholic patients
  475. Forensic Psychiatric Organization in Finland
  476. Suicidal behavior in patients with schizophrenia is related to COMT polymorphism
  477. Ethanol modulates evoked dopamine release in mouse nucleus accumbens: dependence on social stress and dose
  478. Regional cerebral blood flow during exposure to food in obese binge eating women
  479. CYP2A6 genotype and smoking
  480. A volumetric MRI study of the hippocampus in type 1 and 2 alcoholism
  481. Metabolism of [ 123 I]epidepride may affect brain dopamine D 2 receptor imaging with single-photon emission tomography
  482. Association Between the Functional Polymorphism of Catechol‐O‐Methyltransferase Gene and Alcohol Consumption Among Social Drinkers
  483. Association Between the Functional Polymorphism of Catechol-O-Methyltransferase Gene and Alcohol Consumption Among Social Drinkers
  484. Pharmacological Intervention for Preventing Violence Among the Mentally Ill with Secondary Alcohol-And Drug-Use Disorders
  485. Lack of association between the functional variant of the catechol-o-methyltransferase (COMT) gene and early-onset alcoholism associated with severe antisocial behavior
  486. Reversed Hemispheric Asymmetry of Auditory N100m in Schizophrenics
  487. Dopamine-transporter density in nucleus accumbens of type-1 alcoholics
  488. Quantitative MRI of the hippocampus and amygdala in severe depression
  489. Dopamine transporter and D 2 -receptor density in late-onset alcoholism
  490. Erratum to “Mortality among habitually violent offenders”
  491. Iodine-123 labelled PE2I for dopamine transporter imaging: influence of age in healthy subjects
  492. Transient Syncope and ECG Changes Associated With the Concurrent Administration of Clozapine and Diazepam
  493. Outcome of different types of long-term antidepressant treatments: a 3-year follow-up study of 14 182 patients
  494. Pindolol and Major Affective Disorders
  495. Association between low activity serotonin transporter promoter genotype and early onset alcoholism with habitual impulsive violent behavior
  496. Striatal dopamine transporter density in major depression
  497. Dopamine transporter availability and depressive symptoms during alcohol withdrawal
  498. Maternal Smoking During Pregnancy and Risk of Criminal Behavior Among Adult Male Offspring in the Northern Finland 1966 Birth Cohort
  499. Association between the functional variant of the catechol-O-methyltransferase (COMT) gene and type 1 alcoholism
  500. Serum testosterone levels, mental disorders and criminal behaviour
  501. Reply
  502. Mortality among habitually violent offenders
  503. Is a Large Body Size During Childhood a Risk Factor for Later Aggression?
  504. Comparison of Iodine-123 Labelled Nor-β-CIT and β-CIT as Potential Radioligands for Serotonin Transporter Imaging
  505. Schizophrenia and seasonality of admissions: the Northern Finland 1966 birth cohort study
  506. Altered Parallel Auditory Processing in Schizophrenia Patients
  507. Increasing homicide rate in Finland accompanied by decreasing seasonality over the period 1957–95
  508. Chronic pindolol treatment and major affective disorders
  509. Abnormal structure of human striatal dopamine re-uptake sites in habitually violent alcoholic offenders: a fractal analysis
  510. 83 Altered frontal lobe function suggested by erp generator analysis in impulsive violent alcoholics
  511. Fentanyl decreases ?-CIT binding to the dopamine transporter
  512. Imaging the structure of the striatum: a fractal approach to SPECT image interpretation
  513. Seasonal variation in suicide occurrence in Finland
  514. Secular trends in the rates and seasonality of violent and nonviolent suicide occurrences in Finland during 1980–95
  515. Pharmacokinetics and dosimetry of iodine-123 labelled PE2I in humans, a radioligand for dopamine transporter imaging
  516. Resersal of cerebral asymmetry in schizophrenia measured with magnetoencephalography
  517. The metabolism of iodine-123 labelled 3-(5-cyclopropyl-1,2,4-oxadiazo-3-yl)-7-iodo-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine (NNC 13-8241) measured in human plasma is only minor
  518. Striatal presynaptic dopamine function in type 1 alcoholics measured with positron emission tomography
  519. The incidence and onset-age of hospitalized bipolar affective disorder in Finland
  520. Schizophrenia, alcohol abuse and violent behaviour
  521. Change in monoamine transporter density related to clinical recovery: A case-control study
  522. Fractal analysis – a new approach in brain receptor imaging
  523. Juvenile mortality, mental disturbances and criminality: a prospective study of the Northern Finland 1966 birth cohort
  524. Parental age gap and child sex ratio—Fact or fiction?
  525. Schizophrenia, Alcohol Abuse, and Violent Behavior: A 26-Year Followup Study of an Unselected Birth Cohort
  526. Iodine-123 labeled nor-?-CIT as a potential tracer for serotonin transporter imaging in the human brain with single-photon emission tomography
  527. Seasonal Variation in the Occurrence of Homicide in Finland
  528. Single-photon emission tomography imaging of monoamine transporters in impulsive violent behaviour
  529. Cerebral benzodiazepine receptor binding and distribution in generalized anxiety disorder: a fractal analysis
  530. Fractal analysis of striatal dopamine re-uptake sites
  531. Fractal analysis of striatal dopamine re-uptake sites
  532. Seasonal variation of homicide occurrence in Finland
  533. Specific major mental disorders and criminality: a 26-year prospective study of the 1966 northern Finland birth cohort
  534. Striatal and extrastriatal imaging of dopamine D 2 receptors in the living human brain with [ 123 I]epidepride single-photon emission tomography
  535. Striatal and extrastriatal imaging of dopamine D2 receptors in the living human brain with [123I]epidepride single-photon emission tomography
  536. Dopamine reuptake site densities in patients with social phobia
  537. Schizophrenia, alcohol abuse and violent behaviour
  538. Psychiatric disorders and violent behavior
  539. The predictors of schizophrenia in the 1966 Northern Finland birth cobort study
  540. Impaired adaptation to external input in impulsive violent alcoholics
  541. Characterization of C-11 or I-123 Labelled β-CIT‐FP and β-CIT‐FE Metabolism Measured in Monkey and Human Plasma. Identification of Two Labelled Metabolites with HPLC
  542. Characterization of C-11 or I-123 Labelled ?-CIT-FP and ?-CIT-FE Metabolism Measured in Monkey and Human Plasma. Identification of Two Labelled Metabolites with HPLC
  543. Forensic psychotherapy
  544. Serotonergic modulation of striatal D2 dopamine receptor binding in humans measured with positron emission tomography
  545. Initial human studies with single-photon emission tomography using iodine-123 labelled 3-(5-cyclopropyl-1,2,4-oxadiazo-3-yl)-7-iodo-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]-benzodiazepine (NNC 13-8241)
  546. Mental Disorders and Homicidal Behavior in Finland
  547. Risk of homicidal behavior among discharged forensic psychiatric patients
  548. Factors associated with homicide recidivism in a 13-year sample of homicide offenders in Finland
  549. Low incidence of mania in northern Finland
  550. Schizophrenia and Homicidal Behavior
  551. Citalopram in the Treatment of Alcoholism: a Double-blind Placebo-controlled Study
  552. Quantitative Risk Assessment of Homicidal Behaviour
  553. Homicidal behaviour and mental disorders
  554. The metabolite pattern of [123I]β-CIT determined with a gradient HPLC method
  555. Drs. Tiihonen and Kuikka Reply
  556. Altered striatal dopamine re-uptake site densities in habitually violent and non-violent alcoholics
  557. Iodine-123 labelledN-(2-fluoroethyl)-2?-carbomethoxy-3?-(4-iodophenyl)nortropane for dopamine transporter imaging in the living human brain
  558. Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia
  559. Imaging of serotonin and dopamine transporters in the living human brain
  560. Lipophilic metabolite of [123I]β‐CIT in human plasma may obstruct quantitation of the dopamine transporter
  561. Risk of homicidal behaviour among persons convicted of homicide
  562. Altered cerebral blood flow during hysterical paresthesia
  563. Carbamazepine-induced Changes in Plasma Levels of Neuroleptics
  564. Increase in cerebral blood flow of right prefrontal cortex in man during orgasm
  565. Eltoprazine for aggression in schizophrenia and mental retardation
  566. Long-Term Effects of Bilateral Frontal Lobe Lesions from Neuropsychiatric and Neuroradiological Aspects
  567. Magnetoencephalographic localization of epileptic cortex—impact on surgical treatment
  568. Fast decrement with stimulus repetition in ERPs generated by neuronal systems involving somatosensory SI and SII cortices: Electric and magnetic evoked response recordings in humans
  569. Neuromagnetic mismatch fields to single and paired tones
  570. Eosinophilia associated with clozapine
  571. Magnetoencephalographic 10-Hz rhythm from the human auditory cortex
  572. Reply
  573. Localization of epileptic foci using a large‐area magnetometer and functional brain anatomy
  574. Separate finger representations at the human second somatosensory cortex
  575. Early deflections of cerebral magnetic responses to median nerve stimulation
  576. Evoked responses of human auditory cortex may be enhanced by preceding stimuli
  577. Multichannel detection of magnetic compound action fields of median and ulnar nerves
  578. Paired Tone Presentation Enhances Responses of Human Auditory Cortex to Rare Frequency Changes
  579. Magnetic mu rhythm in man
  580. Evoked and Spontaneous Magnetic Activity of the Human Somatosensory Cortex
  581. Molecular characterization of a Y;15 translocation segregating in a family